Orencia available as prefilled syringes for subcutaneous administration

BMS has launched a prefilled syringe presentation of the immunomodulator Orencia (abatacept) for subcutaneous administration in adults with rheumatoid arthritis (RA).

Abatacept is recommended by NICE but only in patients with severe RA who have responded inadequately to (or who have not tolerated) other DMARDS, including methotrexate and a TNF inhibitor, and in whom rituximab is contraindicated or not tolerated.
Abatacept is recommended by NICE but only in patients with severe RA who have responded inadequately to (or who have not tolerated) other DMARDS, including methotrexate and a TNF inhibitor, and in whom rituximab is contraindicated or not tolerated.

Orencia (abatacept) is indicated for use in adults with moderate to severe active rheumatoid arthritis who have responded inadequately to one or more DMARDS, including methotrexate and a TNF inhibitor.

Licensed dose

Treatment should be initiated with a loading dose of abatacept by intravenous infusion. Patients should receive their first 125mg subcutaneous injection within a day of the infusion, which is then followed by 125mg injections once weekly. 

Subcutaneous formulation non-inferior to intravenous administration

In a double-blind randomised phase IIIb study in 1,457 patients, the subcutaneous formulation demonstrated non-inferiority to intravenous infusion when given monthly, following an initial loading dose by intravenous infusion.

Patients achieved similar clinical responses, measured using ACR criteria, and investigators found proportions of adverse events were comparable in the two treatment arms, with low rates of (mostly mild) injection site reactions for both routes.

Not suitable for paediatric patients

Orencia is also licensed for the treatment of severe active polyarticular juvenile idiopathic arthritis in children but the subcutaneous route should not be used in this setting as safety and efficacy have not been established.

View Orencia drug record

Further information: Bristol-Myers Squibb Pharmaceuticals Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...